2024
Estimated Health and Economic Outcomes of Racial and Ethnic Tuberculosis Disparities in US-Born Persons
Swartwood N, Li Y, Regan M, Marks S, Barham T, Asay G, Cohen T, Hill A, Horsburgh C, Khan A, McCree D, Myles R, Salomon J, Self J, Menzies N. Estimated Health and Economic Outcomes of Racial and Ethnic Tuberculosis Disparities in US-Born Persons. JAMA Network Open 2024, 7: e2431988. PMID: 39254977, PMCID: PMC11388029, DOI: 10.1001/jamanetworkopen.2024.31988.Peer-Reviewed Original ResearchConceptsUS-born personsEthnic disparitiesCase-fatality rateTB deathsTB casesTB incidenceSex-adjusted incidenceNational TB surveillance dataTB surveillance dataQuality-adjusted life yearsDistrict of ColumbiaTB disparitiesHealth outcomesEconomic outcomesFuture healthOutcome of TBUS-bornTB outcomesEstimate healthLife yearsSocietal costsTB burdenSocietal perspectiveGeneralized additive regression modelsGoal attainment
2021
The impact of COVID-19 on TB: a review of the data
McQuaid C, Vassall A, Cohen T, Fiekert K, COVID/TB Modelling Working Group *, White R. The impact of COVID-19 on TB: a review of the data. The International Journal Of Tuberculosis And Lung Disease 2021, 25: 436-446. PMID: 34049605, PMCID: PMC8171247, DOI: 10.5588/ijtld.21.0148.Peer-Reviewed Original Research
2012
Population Health Impact and Cost-Effectiveness of Tuberculosis Diagnosis with Xpert MTB/RIF: A Dynamic Simulation and Economic Evaluation
Menzies NA, Cohen T, Lin HH, Murray M, Salomon JA. Population Health Impact and Cost-Effectiveness of Tuberculosis Diagnosis with Xpert MTB/RIF: A Dynamic Simulation and Economic Evaluation. PLOS Medicine 2012, 9: e1001347. PMID: 23185139, PMCID: PMC3502465, DOI: 10.1371/journal.pmed.1001347.Peer-Reviewed Original ResearchConceptsMultidrug-resistant TBCost-effectiveness ratioInitial diagnosisXpert MTB/RIF testMTB/RIF testXpert MTB/RIFIntroduction of XpertTB natural historyTB-HIV coinfectionMultidrug-resistant tuberculosisHigh HIV prevalenceMTB/RIFHealth system costsImplementation of XpertHealth impactsPopulation health impactCost-effectiveness resultsLong-term transmission dynamicsWorld Health OrganizationAntiretroviral therapyTB casesTB deathsTB morbidityHIV prevalenceRIF test